Some pharmacological and biochemical properties of γ-morpholino-butyrophenone (NSD 2023), a new monoamine oxidase inhibitor
- 1 March 1968
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 17 (3), 369-384
- https://doi.org/10.1016/0006-2952(68)90247-5
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- A rapid microfluorimetric determination of monoamine oxidaseBiochemical Pharmacology, 1965
- Pharmacological and Toxicological Studies on γ‐(4‐methylpiperidino)‐p‐fluorobutyrophenone (FG 5111) ‐ a New Neuroleptic AgentActa Pharmacologica et Toxicologica, 1965
- THE EFFECT OF HEAT, INHIBITORS, AND RIBOFLAVIN DEFICIENCY ON MONOAMINE OXIDASECanadian Journal of Biochemistry, 1965
- Actinomycin sensitivity in Escherichiacoli produced by EDTABiochemical and Biophysical Research Communications, 1965
- An analysis of the interaction of reversible and irreversible monoamine oxidase inhibitorsBiochemical Pharmacology, 1964
- Light-An Essential Factor in the Trihydroxyindole-Spectrophotofluorometric Assay of NorepinephrineJournal of Pharmaceutical Sciences, 1963
- RELATION BETWEEN NOREPINEPHRINE ACCUMULATION OR DEPLETION AND BLOOD PRESSURE RESPONSES IN THE CAT AND RAT FOLLOWING PARGYLINE ADMINISTRATIONAnnals of the New York Academy of Sciences, 1963
- INHIBITION OF MONOAMINE OXIDASE BY 2‐METHYL‐3‐PIPERIDINOPYRAZINEAnnals of the New York Academy of Sciences, 1963
- ACTIVITY OF MONOAMINE OXIDASE IN RELATION TO THE 5‐HYDROXYTRYPTAMINE AND NOREPINEPHRINE CONTENT OF THE RAT BRAIN*Journal of Neurochemistry, 1961
- The interaction between reversible and irreversible monoamine oxidase inhibitorsBiochemical Pharmacology, 1960